Cargando…

Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody

The quest to develop an effective malaria vaccine remains a major priority in the fight against global infectious disease. An approach with great potential is a transmission-blocking vaccine which induces antibodies that prevent establishment of a productive infection in mosquitos that feed on infec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lennartz, Frank, Brod, Florian, Dabbs, Rebecca, Miura, Kazutoyo, Mekhaiel, David, Marini, Arianna, Jore, Matthijs M., Søgaard, Max M., Jørgensen, Thomas, de Jongh, Willem A., Sauerwein, Robert W., Long, Carole A., Biswas, Sumi, Higgins, Matthew K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148045/ https://www.ncbi.nlm.nih.gov/pubmed/30237518 http://dx.doi.org/10.1038/s41467-018-06340-9

Ejemplares similares

Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies
por: Ko, Kuang-Ting, et al.
Publicado: (2022)

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45
por: Kundu, Prasun, et al.
Publicado: (2018)

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum
por: Singh, Susheel K., et al.
Publicado: (2019)

Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice
por: Brod, Florian, et al.
Publicado: (2018)

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system
por: Lee, Shwu-Maan, et al.
Publicado: (2020)

Poor CD4(+) T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans
por: Zaric, Marija, et al.
Publicado: (2021)

A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria
por: Mamedov, Tarlan, et al.
Publicado: (2019)

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
por: Singh, Kavita, et al.
Publicado: (2020)

Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses
por: McLeod, Brandon, et al.
Publicado: (2022)

The Dynamics of Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania
por: Bousema, Teun, et al.
Publicado: (2010)

Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes
por: Fabra-García, Amanda, et al.
Publicado: (2023)

Rare Alleles and Signatures of Selection on the Immunodominant Domains of Pfs230 and Pfs48/45 in Malaria Parasites From Western Kenya
por: Ochwedo, Kevin O., et al.
Publicado: (2022)

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response
por: Marini, Arianna, et al.
Publicado: (2019)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
por: de Graaf, Hans, et al.
Publicado: (2021)

Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana
por: Acquah, Festus K., et al.
Publicado: (2017)

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology
por: Li, Yuanyuan, et al.
Publicado: (2016)

Profiling the Quality and Quantity of Naturally Induced Antibody Responses Against Pfs230 and Pfs48/45 Among Non-Febrile Children Living in Southern Ghana: A Longitudinal Study
por: Broni, Fermin K., et al.
Publicado: (2021)

Identification of domains within Pfs230 that elicit transmission blocking antibody responses
por: Tachibana, Mayumi, et al.
Publicado: (2019)

A human antibody epitope map of the malaria vaccine antigen Pfs25
por: Shukla, Niharika, et al.
Publicado: (2023)

The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
por: Miura, Kazutoyo, et al.
Publicado: (2007)

A Potent Malaria Transmission Blocking Vaccine Based on Codon Harmonized Full Length Pfs48/45 Expressed in Escherichia coli
por: Chowdhury, Debabani Roy, et al.
Publicado: (2009)

Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine
por: Dickey, Thayne H., et al.
Publicado: (2023)

New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission
por: McGuire, Kathleen A., et al.
Publicado: (2017)

Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

Development and Qualification of an Antigen Integrity Assay for a Plasmodium falciparum Malaria Transmission Blocking Vaccine Candidate, Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission
por: Kapoor, Neeraj, et al.
Publicado: (2018)

N-Terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2017)

Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates
por: Lee, Shwu-Maan, et al.
Publicado: (2016)

TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25
por: Thompson, Elizabeth A., et al.
Publicado: (2018)

A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle
por: Salinas, Nichole D., et al.
Publicado: (2023)

Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages
por: Huang, Wei-Chiao, et al.
Publicado: (2022)

Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25
por: McLeod, Brandon, et al.
Publicado: (2019)

Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45
por: Pritsch, Michael, et al.
Publicado: (2016)

Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230
por: Ivanochko, Danton, et al.
Publicado: (2023)

Immunoreactivity of Sera From Low to Moderate Malaria-Endemic Areas Against Plasmodium vivax rPvs48/45 Proteins Produced in Escherichia coli and Chinese Hamster Ovary Systems
por: Arévalo-Herrera, Myriam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c55gb90vpifa1cu6q802bqklj4